Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAYNYSE / NASDAQHealthcareSmall cap

$16.12+$0.21 (+1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$3.2B
P/E
-11.5x
EV / EBITDA
-10.4x
Revenue
$15.4M
Net margin
-1800.6%
ROCE
-50.8%

+152.7% over the last year

Relay Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-12.6%
3M
-18.2%
6M
+23.8%
1Y
+152.7%
5Y
-53.3%

52-week range

Day change +$0.21 (+1.3%) from $16 to $16 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RLAY, bought on each weekday since 2021.

News & filings

What Relay Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 276 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 53.4% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Read moreShow less

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
173.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.2B
P/E
-11.5x
P/B
5.6x
EV / EBITDA
-10.4x
EV / Sales
203.0x
P/S
206.4x
52-week high
$20.75
52-week low
$6.38

Profitability

Operating margin
-1971.6%
Net margin
-1800.6%
EBITDA margin
-1948.4%
ROE
-48.8%
ROCE
-50.8%
ROIC
-46.4%
ROA
-44.5%
Asset turnover
0.02

Growth

Revenue
$15.4M
Revenue growth, 1Y
53.4%
Revenue CAGR, 3Y
123.2%
Net profit growth, 1Y
-18.1%
Free cash flow
-$235.9M

Solvency

Current ratio
22.61
Debt / Equity
0.06
Debt / Assets
0.05
CFO / Net profit
0.85
Cash / Market cap
2.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$15.4M
Gross profit$15.4M
Operating expenses$318.1M
Research and development$261.4M
Selling, general and administrative$56.7M
Operating income-$302.7M
Interest and other$26.3M
Pretax income-$276.5M
Tax and other$0.00
Net income-$276.5M

Revenue and net profit

Revenue grew 53.4% in FY2025; net profit is the dashed line.

Relay Therapeutics, Inc. revenue and net profit by fiscal year
Relay Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.4M-$290.5M
FY2023$25.5M-$342.0M
FY2024$10.0M-$337.7M
FY2025$15.4M-$276.5M

Cash flows

FY2025: -$235.5M from operations, -$235.9M free after investment (dashed).

Relay Therapeutics, Inc. operating and free cash flow by fiscal year
Relay Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$229.5M-$238.6M
FY2023-$300.3M-$304.4M
FY2024-$249.1M-$251.1M
FY2025-$235.5M-$235.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$15.4M+53.4%1Y
EBITDA
-$299.2M
Net profit
-$276.5M
Cash from operations
-$235.5M
Free cash flow
-$235.9M
Revenue CAGR, 3Y
123.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$15.4M-$299.2M-$276.5M-$235.9M-48.8%+53.4%-18.1%

Monthly returns

Month-by-month returns of RLAY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$621.3M
Liabilities$54.3M
Equity$567.1M
Paid-in capital$2.6B
Retained earnings-$2.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RLAY highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Relay Therapeutics, Inc. (this company)203.0x

Not shown (no positive earnings and no EV / Sales): Denali Therapeutics Inc., Dyne Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Relay Therapeutics, Inc.RLAYthis company$3.2B-11.5x5.6x-48.8%-10.4x
Beam Therapeutics Inc.BEAM$3.4B-42.2x2.7x-6.5%-9.0x
Tango Therapeutics, Inc.TNGX$3.2B-31.5x9.3x-29.3%-28.7x
Denali Therapeutics Inc.DNLI$3.2B-6.2x3.2x-50.6%-5.6x
Haemonetics CorporationHAE$3.2B32.6x4.0x12.2%15.5x
Option Care Health, Inc.OPCH$3.2B15.2x2.4x15.6%10.3x
Alignment Healthcare, Inc.ALHC$3.1B—17.4x-0.4%62.7x
Dyne Therapeutics, Inc.DYN$3.0B-6.8x3.1x-45.9%-5.3x
Warby Parker Inc.WRBY$3.0B1803.7x8.0x0.4%64.7x
Peer median—-6.2x3.6x-3.4%2.5x

Year-to-date ROI

RLAY since 1 January, against earlier years.

Historical volatility

RLAY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Relay Therapeutics, Inc. operating margin by fiscal year
Relay Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-22532.6%
FY2023-1485.0%
FY2024-3852.8%
FY2025-1971.0%
LineFY2025
Operating expensesOperating Expense$318.1M
Research and developmentResearch And Development$261.4M
Total expensesTotal Expenses$318.1M
Pretax incomePretax Income-$276.5M

Learn while you research

Academy chapters picked for Relay Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing53% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →